MERCK & CO., INC. | ||||||
CONSOLIDATED STATEMENT OF INCOME - GAAP | ||||||
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) | ||||||
(UNAUDITED) | ||||||
Table 1 | ||||||
On June 2, 2021, Merck completed the spinoff of products from its women's health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon & Co. (Organon) through a distribution of Organon's publicly traded stock to company shareholders. The historical results of the women's health, biosimilars and established brands businesses that were contributed to Organon in the spin-off are excluded from sales and expenses below and reflected as discontinued operations in the company's Consolidated Statements of Income provided below. | ||||||
GAAP | % Change | GAAP | % Change | |||
3Q21 | 3Q20 | Sep YTD 2021 | Sep YTD 2020 | |||
Sales | $ 13,154 | $ 10,929 | 20% | $ 35,183 | $ 30,570 | 15% |
Costs, Expenses and Other | ||||||
Cost of sales | 3,450 | 3,013 | 15% | 9,752 | 8,589 | 14% |
Selling, general and administrative | 2,336 | 2,060 | 13% | 6,804 | 6,336 | 7% |
Research and development | 2,445 | 3,349 | -27% | 9,177 | 7,609 | 21% |
Restructuring costs (1) | 107 | 113 | -5% | 487 | 265 | 84% |
Other (income) expense, net | (450) | (312) | 44% | (1,007) | (637) | 58% |
Income from Continuing Operations Before Taxes | 5,266 | 2,706 | 95% | 9,970 | 8,408 | 19% |
Income Tax Provision | 695 | 380 | 1,436 | 1,271 | ||
Net Income from Continuing Operations | 4,571 | 2,326 | 97% | 8,534 | 7,137 | 20% |
Less: Net Income Attributable to Noncontrolling Interests | 4 | 2 | 9 | 1 | ||
Net Income from Continuing Operations Attributable to Merck & Co., Inc. | $ 4,567 | $ 2,324 | 97% | $ 8,525 | $ 7,136 | 19% |
Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests | $ -0 | $ 617 | * | $ 766 | $ 2,025 | -62% |
Net Income Attributable to Merck & Co., Inc. | $ 4,567 | $ 2,941 | 55% | $ 9,291 | $ 9,161 | 1% |
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders: | ||||||
Income from Continuing Operations | $ 1.81 | $ 0.92 | 97% | $ 3.37 | $ 2.82 | 20% |
Income from Discontinued Operations | $ -0 | $ 0.24 | * | $ 0.30 | $ 0.80 | -63% |
Net Income | $ 1.81 | $ 1.16 | 56% | $ 3.67 | $ 3.62 | 1% |
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders: | ||||||
Income from Continuing Operations | $ 1.80 | $ 0.92 | 96% | $ 3.36 | $ 2.81 | 20% |
Income from Discontinued Operations | $ -0 | $ 0.24 | * | $ 0.30 | $ 0.80 | -63% |
Net Income | $ 1.80 | $ 1.16 | 55% | $ 3.66 | $ 3.61 | 1% |
Average Shares Outstanding | 2,530 | 2,529 | 2,531 | 2,530 | ||
Average Shares Outstanding Assuming Dilution | 2,536 | 2,538 | 2,539 | 2,541 | ||
Tax Rate from Continuing Operations (2) | 13.2% | 14.0% | 14.4% | 15.1% | ||
* 100% or greater | ||||||
(1) Represents separation and other related costs associated with restructuring activities under the company's formal restructuring programs. | ||||||
(2) The effective income tax rate for the first nine months of 2021 reflects the unfavorable impact of a charge for the acquisition of Pandion Therapeutics, Inc. for which no tax benefit was recognized and a net tax benefit of $207 million related to the settlement of certain federal income tax matters. |
MERCK & CO., INC. | |||||||||||||
CONSOLIDATED STATEMENT OF INCOME - GAAP | |||||||||||||
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) | |||||||||||||
(UNAUDITED) | |||||||||||||
Table 1a | |||||||||||||
2021 | 2020 | % Change | |||||||||||
1Q | 2Q | 3Q | 4Q | Sep YTD | 1Q | 2Q | 3Q | Sep YTD | 4Q | Full Year | 3Q | Sep YTD | |
June YTD | June YTD | ||||||||||||
. | |||||||||||||
Sales | $ 10,627 | $ 11,402 | $ 13,154 | $ 35,183 | $ 10,288 | $ 9,353 | $ 10,929 | $ 30,570 | $ 10,948 | $ 41,518 | 20% | 15% | |
Costs, Expenses and Other | |||||||||||||
Cost of sales | 3,199 | 3,104 | 3,450 | 9,752 | 2,829 | 2,747 | 3,013 | 8,589 | 5,029 | 13,618 | 15% | 14% | |
Selling, general and administrative | 2,187 | 2,281 | 2,336 | 6,804 | 2,191 | 2,085 | 2,060 | 6,336 | 2,619 | 8,955 | 13% | 7% | |
Research and development | 2,412 | 4,321 | 2,445 | 9,177 | 2,175 | 2,085 | 3,349 | 7,609 | 5,788 | 13,397 | -27% | 21% | |
Restructuring costs | 297 | 82 | 107 | 487 | 70 | 82 | 113 | 265 | 310 | 575 | -5% | 84% | |
Other (income) expense, net | (455) | (103) | (450) | (1,007) | 62 | (387) | (312) | (637) | (253) | (890) | 44% | 58% | |
Income (Loss) from Continuing Operations Before Taxes | 2,987 | 1,717 | 5,266 | 9,970 | 2,961 | 2,741 | 2,706 | 8,408 | (2,545) | 5,863 | 95% | 19% | |
Income Tax Provision | 238 | 503 | 695 | 1,436 | 495 | 396 | 380 | 1,271 | 69 | 1,340 | |||
Net Income (Loss) from Continuing Operations | 2,749 | 1,214 | 4,571 | 8,534 | 2,466 | 2,345 | 2,326 | 7,137 | (2,614) | 4,523 | 97% | 20% | |
Less: Net Income (Loss) Attributable to Noncontrolling Interests | 4 | 1 | 4 | 9 | (5) | 4 | 2 | 1 | 3 | 4 | |||
Net Income (Loss) from Continuing Operations Attributable to Merck & Co., Inc. | 2,745 | 1,213 | 4,567 | 8,525 | 2,471 | 2,341 | 2,324 | 7,136 | (2,617) | 4,519 | 97% | 19% | |
Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests | 434 | 332 | -0 | 766 | 748 | 661 | 617 | 2,025 | 523 | 2,548 | * | -62% | |
Net Income (Loss) Attributable to Merck & Co., Inc. | $ 3,179 | $ 1,545 | $ 4,567 | $ 9,291 | $ 3,219 | $ 3,002 | $ 2,941 | $ 9,161 | $ (2,094) | $ 7,067 | 55% | 1% | |
Basic Earnings (Loss) per Common Share Attributable to Merck & Co., Inc. Common Shareholders: | |||||||||||||
Income (Loss) from Continuing Operations | $ 1.08 | $ 0.48 | $ 1.81 | $ 3.37 | $ 0.98 | $ 0.93 | $ 0.92 | $ 2.82 | $ (1.03) | $ 1.79 | 97% | 20% | |
Income from Discontinued Operations | 0.17 | 0.13 | - 0 | 0.30 | 0.30 | 0.26 | 0.24 | 0.80 | 0.21 | 1.01 | * | -63% | |
Net Income (Loss) | $ 1.26 | $ 0.61 | $ 1.81 | $ -0 | $ 3.67 | $ 1.27 | $ 1.19 | $ 1.16 | $ 3.62 | $ (0.83) | $ 2.79 | 56% | 1% |
Earnings (Loss) per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders: | |||||||||||||
Income (Loss) from Continuing Operations | $ 1.08 | $ 0.48 | $ 1.80 | $ 3.36 | $ 0.97 | $ 0.92 | $ 0.92 | $ 2.81 | $ (1.03) | $ 1.78 | 96% | 20% | |
Income from Discontinued Operations | 0.17 | 0.13 | - 0 | 0.30 | 0.29 | 0.26 | 0.24 | 0.80 | 0.21 | 1.00 | * | -63% | |
Net Income (Loss) | $ 1.25 | $ 0.61 | $ 1.80 | $ -0 | $ 3.66 | $ 1.26 | $ 1.18 | $ 1.16 | $ 3.61 | $ (0.83) | $ 2.78 | 55% | 1% |
Average Shares Outstanding | 2,531 | 2,533 | 2,530 | 2,531 | 2,533 | 2,527 | 2,529 | 2,530 | 2,530 | 2,530 | |||
Average Shares Outstanding Assuming Dilution (1) | 2,541 | 2,540 | 2,536 | 2,539 | 2,547 | 2,536 | 2,538 | 2,541 | 2,530 | 2,541 | |||
Tax Rate from Continuing Operations | 8.0% | 29.3% | 13.2% | 14.4% | 16.7% | 14.4% | 14.0% | 15.1% | -2.7% | 22.9% | |||
* 100% or greater | |||||||||||||
Sum of quarterly amounts may not equal year-to-date amounts due to rounding. | |||||||||||||
(1) Because the company recorded a net loss in the fourth quarter of 2020, no potential dilutive common shares were used in the computation of loss per common share assuming dilution as the effect would have been anti-dilutive. Income from discontinued operations was also computed using average common shares outstanding. |
MERCK & CO., INC. | |||||||||||
THIRD QUARTER AND NINE MONTHS ENDED SEPTEMBER 30, 2021 GAAP TO NON-GAAP RECONCILIATION - CONTINUING OPERATIONS | |||||||||||
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) | |||||||||||
(UNAUDITED) | |||||||||||
Table 2a | |||||||||||
The table below reflects a reconciliation of GAAP to non-GAAP financial information on a continuing operations basis. As Organon results are reflected within discontinued operations, they are excluded from the financial information provided below. | |||||||||||
GAAP | Acquisition and Divestiture-Related Costs (1) | Restructuring Costs (2) | (Income) Loss from Investments in Equity Securities | Certain Other Items | Adjustment Subtotal | Non-GAAP | |||||
Third Quarter | |||||||||||
Cost of sales | $ 3,450 | 346 | 48 | 394 | $ 3,056 | ||||||
Selling, general and administrative | 2,336 | 61 | 5 | 66 | 2,270 | ||||||
Research and development | 2,445 | 48 | 8 | (87) | (4) | (31) | 2,476 | ||||
Restructuring costs | 107 | 107 | 107 | -0 | |||||||
Other (income) expense, net | (450) | (10) | (684) | (694) | 244 | ||||||
Income From Continuing Operations Before Taxes | 5,266 | (445) | (168) | 684 | 87 | 158 | 5,108 | ||||
Income Tax Provision (Benefit) | 695 | (96) | (5) | (26) | (5) | 151 | (5) | 1 | (5) | 30 | 665 |
Net Income from Continuing Operations | 4,571 | (349) | (142) | 533 | 86 | 128 | 4,443 | ||||
Net Income from Continuing Operations Attributable to Merck & Co., Inc. | 4,567 | -0 | (349) | (142) | 533 | 86 | 128 | 4,439 | |||
Earnings per Common Share Assuming Dilution from Continuing Operations | $ 1.80 | (0.14) | (0.06) | 0.21 | 0.04 | 0.05 | $ 1.75 | ||||
Tax Rate | 13.2% | 13.0% | |||||||||
Sep YTD | |||||||||||
Cost of sales | $ 9,752 | 1,188 | 113 | 225 | (3) | 1,526 | $ 8,226 | ||||
Selling, general and administrative | 6,804 | 96 | 9 | 105 | 6,699 | ||||||
Research and development | 9,177 | 82 | 21 | 1,678 | (4) | 1,781 | 7,396 | ||||
Restructuring costs | 487 | 487 | 487 | -0 | |||||||
Other (income) expense, net | (1,007) | 79 | (1,503) | (1,424) | 417 | ||||||
Income From Continuing Operations Before Taxes | 9,970 | (1,445) | (630) | 1,503 | (1,903) | (2,475) | 12,445 | ||||
Income Tax Provision (Benefit) | 1,436 | (283) | (5) | (82) | (5) | 331 | (5) | (259) | (5) | (293) | 1,729 |
Net Income from Continuing Operations | 8,534 | (1,162) | (548) | 1,172 | (1,644) | (2,182) | 10,716 | ||||
Net Income from Continuing Operations Attributable to Merck & Co., Inc. | 8,525 | -0 | (1,162) | (548) | 1,172 | (1,644) | (2,182) | 10,707 | |||
Earnings per Common Share Assuming Dilution from Continuing Operations | $ 3.36 | (0.46) | (0.22) | 0.46 | (0.65) | (0.86) | $ 4.22 | ||||
Tax Rate | 14.4% | 13.9% | |||||||||
Only the line items that are affected by non-GAAP adjustments are shown. | |||||||||||
Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors' understanding of the company's results as it permits investors to understand how management assesses performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management's annual compensation is derived in part using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. | |||||||||||
(1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect acquisition and divestiture-related costs. Amounts included in research and development expenses primarily reflect expenses for the amortization of intangible assets. Amounts included in other (income) expense, net, for the third quarter and nine months period primarily reflect an increase in the estimated fair value measurement of liabilities for contingent consideration related to the termination of the Sanofi-Pasteur MSD joint venture. Additionally, the first nine months also includes a loss on a forward exchange contract entered into in conjunction with the Organon spinoff. Amount included in other (income) expense, net, for the nine month period is partially offset by royalty income related to the termination of the Sanofi-Pasteur MSD joint venture. | |||||||||||
(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs. | |||||||||||
(3) Represents charges for the discontinuation of COVID-19 development programs. | |||||||||||
(4) Amounts included in the third quarter and first nine months reflect a $90 million adjustment to deferred tax assets identified in conjunction with the VelosBio Inc. acquisition. Additionally, the first nine months includes a $1.7 billion charge for the acquisition of Pandion Therapeutics, Inc. | |||||||||||
(5) Represent the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. Certain other items for the nine month period also includes a $207 million net tax benefit related to the settlement of certain federal income tax matters. |
&"Times New Roman,Regular"&12&KE8E800Confidential
&"Times New Roman,Regular"&12&KE8E800Confidential
MERCK & CO., INC. | |||||||||||
THIRD QUARTER AND NINE MONTHS ENDED SEPTEMBER 30, 2020 GAAP TO NON-GAAP RECONCILIATION - CONTINUING OPERATIONS | |||||||||||
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) | |||||||||||
(UNAUDITED) | |||||||||||
Table 2b | |||||||||||
The table below reflects a reconciliation of GAAP to non-GAAP financial information on a continuing operations basis. As Organon results are reflected within discontinued operations, they are excluded from the financial information provided below. | |||||||||||
GAAP | Acquisition and Divestiture-Related Costs (1) | Restructuring Costs (2) | (Income) Loss from Investments in Equity Securities | Certain Other Items | Adjustment Subtotal | Non-GAAP | |||||
Third Quarter | |||||||||||
Cost of sales | $ 3,013 | 403 | 38 | 441 | $ 2,572 | ||||||
Selling, general and administrative | 2,060 | 25 | 15 | 40 | 2,020 | ||||||
Research and development | 3,349 | 19 | 19 | 1,082 | (3) | 1,120 | 2,229 | ||||
Restructuring costs | 113 | 113 | 113 | -0 | |||||||
Other (income) expense, net | (312) | (346) | (1) | (347) | 35 | ||||||
Income From Continuing Operations Before Taxes | 2,706 | (447) | (185) | 346 | (1,081) | (1,367) | 4,073 | ||||
Income Tax Provision (Benefit) | 380 | (9) | (4) | (25) | (4) | 76 | (4) | (247) | (4) | (205) | 585 |
Net Income from Continuing Operations | 2,326 | (438) | (160) | 270 | (834) | (1,162) | 3,488 | ||||
Net Income from Continuing Operations Attributable to Merck & Co., Inc. | 2,324 | -0 | (438) | (160) | 270 | (834) | (1,162) | 3,486 | |||
Earnings per Common Share Assuming Dilution from Continuing Operations | $ 0.92 | (0.17) | (0.06) | 0.11 | (0.33) | (0.45) | $ 1.37 | ||||
Tax Rate | 14.0% | 14.4% | |||||||||
Sep YTD | |||||||||||
Cost of sales | $ 8,589 | 1,370 | 131 | 1,501 | $ 7,088 | ||||||
Selling, general and administrative | 6,336 | 182 | 37 | 219 | 6,117 | ||||||
Research and development | 7,609 | (4) | 67 | 1,082 | (3) | 1,145 | 6,464 | ||||
Restructuring costs | 265 | 265 | 265 | -0 | |||||||
Other (income) expense, net | (637) | 52 | (944) | (17) | (909) | 272 | |||||
Income From Continuing Operations Before Taxes | 8,408 | (1,600) | (500) | 944 | (1,065) | (2,221) | 10,629 | ||||
Income Tax Provision (Benefit) | 1,271 | (251) | (4) | (59) | (4) | 208 | (4) | (242) | (4) | (344) | 1,615 |
Net Income from Continuing Operations | 7,137 | (1,349) | (441) | 736 | (823) | (1,877) | 9,014 | ||||
Net Income from Continuing Operations Attributable to Merck & Co., Inc. | 7,136 | -0 | (1,349) | (441) | 736 | (823) | (1,877) | 9,013 | |||
Earnings per Common Share Assuming Dilution from Continuing Operations | $ 2.81 | (0.54) | (0.17) | 0.29 | (0.32) | (0.74) | $ 3.55 | ||||
Tax Rate | 15.1% | 15.2% | |||||||||
Only the line items that are affected by non-GAAP adjustments are shown. | |||||||||||
Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors' understanding of the company's results as it permits investors to understand how management assesses performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management's annual compensation is derived in part using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. | |||||||||||
(1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative (SG&A) expenses reflect acquisition and divestiture-related costs, including $95 million of transaction costs in the nine month period related to the acquisition of Arqule, Inc. Amounts included in research and development expenses primarily reflect a reduction in expenses related to a decrease in the estimated fair value measurement of liabilities for contingent consideration. Amounts included in other (income) expense, net, primarily reflect costs related to increases in the estimated fair value measurement of liabilities for contingent consideration, partially offset by royalty income related to the termination of the Sanofi-Pasteur MSD joint venture. | |||||||||||
(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs. | |||||||||||
(3) Represents expenses for upfront payments related to license and collaboration agreements. | |||||||||||
(4) Represent the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. Acquisition and divestiture-related costs also includes a tax cost of $67 million, representing an adjustment to the tax benefits recorded in conjunction with the 2015 Cubist Pharmaceuticals, Inc. acquisition. |
&"Times New Roman,Regular"&12&KE8E800Confidential
&"Times New Roman,Regular"&12&KE8E800Confidential
MERCK & CO., INC. | ||||||||||||||
FRANCHISE / KEY PRODUCT SALES - CONTINUING OPERATIONS | ||||||||||||||
(AMOUNTS IN MILLIONS) | ||||||||||||||
(UNAUDITED) | ||||||||||||||
Table 3 | ||||||||||||||
2021 | 2020 | 3Q | September YTD | |||||||||||
1Q | 2Q | 3Q | Sep YTD | 1Q | 2Q | 3Q | Sep YTD | 4Q | Full Year | Nom % | Ex-Exch % | Nom % | Ex-Exch % | |
TOTAL SALES (1) | $10,627 | $11,402 | $13,154 | $35,183 | $10,288 | $9,353 | $10,929 | $30,570 | $10,948 | $41,518 | 20 | 19 | 15 | 13 |
PHARMACEUTICAL | 9,238 | 9,980 | 11,496 | 30,714 | 8,905 | 8,178 | 9,714 | 26,797 | 9,813 | 36,610 | 18 | 17 | 15 | 12 |
Oncology | ||||||||||||||
Keytruda | 3,899 | 4,176 | 4,534 | 12,609 | 3,284 | 3,388 | 3,715 | 10,387 | 3,993 | 14,380 | 22 | 21 | 21 | 19 |
Alliance Revenue - Lynparza (2) | 228 | 248 | 246 | 721 | 145 | 178 | 196 | 519 | 206 | 725 | 25 | 25 | 39 | 35 |
Alliance Revenue - Lenvima (2) | 130 | 181 | 188 | 498 | 128 | 151 | 142 | 421 | 158 | 580 | 32 | 30 | 18 | 15 |
Vaccines (3) | ||||||||||||||
Gardasil / Gardasil 9 | 917 | 1,234 | 1,993 | 4,144 | 1,097 | 656 | 1,187 | 2,941 | 998 | 3,938 | 68 | 63 | 41 | 35 |
ProQuad / M-M-R II / Varivax | 449 | 516 | 661 | 1,626 | 435 | 378 | 576 | 1,390 | 488 | 1,878 | 15 | 14 | 17 | 16 |
Pneumovax 23 | 171 | 152 | 277 | 600 | 256 | 117 | 375 | 748 | 339 | 1,087 | -26 | -26 | -20 | -21 |
RotaTeq | 158 | 208 | 227 | 593 | 222 | 168 | 210 | 601 | 196 | 797 | 8 | 7 | -1 | -3 |
Vaqta | 34 | 56 | 48 | 138 | 60 | 28 | 51 | 139 | 31 | 170 | -6 | -6 | -1 | -2 |
Hospital Acute Care | ||||||||||||||
Bridion | 340 | 387 | 369 | 1,096 | 299 | 224 | 320 | 843 | 355 | 1,198 | 16 | 15 | 30 | 27 |
Prevymis | 82 | 93 | 96 | 270 | 60 | 63 | 77 | 200 | 80 | 281 | 23 | 22 | 35 | 31 |
Noxafil | 67 | 66 | 64 | 197 | 94 | 73 | 79 | 247 | 82 | 329 | -19 | -20 | -20 | -23 |
Primaxin | 65 | 60 | 70 | 194 | 51 | 64 | 74 | 189 | 62 | 251 | -6 | -12 | 3 | -4 |
Cancidas | 57 | 54 | 56 | 168 | 55 | 43 | 50 | 148 | 65 | 213 | 13 | 9 | 13 | 8 |
Invanz | 57 | 48 | 53 | 157 | 64 | 43 | 51 | 159 | 53 | 211 | 5 | 0 | -1 | -4 |
Zerbaxa | (8) | (1) | (2) | (11) | 37 | 32 | 43 | 112 | 19 | 130 | -105 | -105 | -110 | -110 |
Immunology | ||||||||||||||
Simponi | 214 | 202 | 203 | 619 | 215 | 191 | 209 | 615 | 223 | 838 | -3 | -5 | 1 | -5 |
Remicade | 85 | 75 | 73 | 233 | 88 | 73 | 82 | 242 | 88 | 330 | -11 | -11 | -4 | -8 |
Neuroscience | ||||||||||||||
Belsomra | 79 | 78 | 81 | 238 | 79 | 84 | 81 | 244 | 83 | 327 | 0 | 3 | -2 | -2 |
Virology | ||||||||||||||
Isentress / Isentress HD | 209 | 192 | 189 | 590 | 245 | 196 | 205 | 646 | 211 | 857 | -8 | -7 | -9 | -9 |
Cardiovascular | ||||||||||||||
Alliance Revenue - Adempas/Verquvo (4) | 74 | 74 | 100 | 248 | 53 | 79 | 83 | 216 | 65 | 281 | 20 | 20 | 15 | 15 |
Adempas (5) | 55 | 74 | 59 | 188 | 56 | 57 | 55 | 167 | 53 | 220 | 7 | 8 | 13 | 7 |
Diabetes (6) | ||||||||||||||
Januvia | 809 | 784 | 852 | 2,445 | 774 | 854 | 821 | 2,449 | 857 | 3,306 | 4 | 3 | 0 | -3 |
Janumet | 486 | 477 | 487 | 1,449 | 503 | 490 | 506 | 1,499 | 472 | 1,971 | -4 | -6 | -3 | -7 |
Other Pharmaceutical (7) | 581 | 546 | 572 | 1,704 | 605 | 548 | 526 | 1,675 | 636 | 2,312 | 9 | 8 | 2 | 1 |
ANIMAL HEALTH | 1,418 | 1,472 | 1,417 | 4,307 | 1,214 | 1,101 | 1,220 | 3,535 | 1,168 | 4,703 | 16 | 14 | 22 | 19 |
Livestock | 819 | 821 | 864 | 2,503 | 739 |
648 tc={CCA1B227-180F-4895-BC6E-35C1D876C08B}: [Threaded comment] Your version of Excel allows you to read this threaded comment; however, any edits to it will get removed if the file is opened in a newer version of Excel. Learn more: https://go.microsoft.com/fwlink/?linkid=870924 Comment: rounding | 758 | 2,145 | 794 | 2,939 | 14 | 12 | 17 | 14 |
Companion Animals | 599 | 651 | 553 | 1,804 | 475 | 453 | 462 | 1,390 | 374 | 1,764 | 20 | 18 | 30 | 26 |
Other Revenues (8) | (29) | (50) | 241 | 162 | 169 | 74 | (5) | 238 | (33) | 205 | * | * | -32 | 88 |
* 200% or greater | ||||||||||||||
Sum of quarterly amounts may not equal year-to-date amounts due to rounding. | ||||||||||||||
(1) Only select products are shown. | ||||||||||||||
(2) Alliance Revenue represents Merck's share of profits, which are product sales net of cost of sales and commercialization costs. | ||||||||||||||
(3) Total Vaccines sales were $1,809 million, $2,293 million, and $3,315 million in the first, second, and third quarter of 2021, respectively, and $2,155 million, $1,418 million, $2,521 million and $2,163 million in the first, second, third and fourth quarters of 2020, respectively. | ||||||||||||||
(4) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. | ||||||||||||||
(5) Net product sales in Merck's marketing territories. | ||||||||||||||
(6) Total Diabetes sales were $1,363 million, $1,330 million, and $1,417 million in the first, second, and third quarter of 2021, respectively, and $1,353 million, $1,418 million, $1,405 million and $1,412 million in the first, second, third and fourth quarters of 2020, respectively. | ||||||||||||||
(7) Includes Pharmaceutical products not individually shown above. | ||||||||||||||
(8) Other Revenues are comprised primarily of third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities. Other Revenues in the third quarter and September year-to-date period of 2021 include $135 million related to the receipt of a milestone payment for an out-licensed product. |
MERCK & CO., INC. | |||||||||
FRANCHISE / KEY PRODUCT SALES - CONTINUING OPERATIONS | |||||||||
THIRD QUARTER 2021 | |||||||||
(AMOUNTS IN MILLIONS) | |||||||||
(UNAUDITED) | |||||||||
Table 3a | |||||||||
Global | U.S. | International | |||||||
3Q 2021 | 3Q 2020 | % Change | 3Q 2021 | 3Q 2020 | % Change | 3Q 2021 | 3Q 2020 | % Change | |
TOTAL SALES (1) | $13,154 | $10,929 | 20 | $6,276 | $5,250 | 20 | $6,878 | $5,679 | 21 |
PHARMACEUTICAL | 11,496 | 9,714 | 18 | 5,670 | 4,842 | 17 | 5,826 | 4,872 | 20 |
Oncology | |||||||||
Keytruda | 4,534 | 3,715 | 22 | 2,580 | 2,157 | 20 | 1,954 | 1,559 | 25 |
Alliance Revenue - Lynparza (2) | 246 | 196 | 25 | 129 | 107 | 21 | 117 | 89 | 31 |
Alliance Revenue - Lenvima (2) | 188 | 142 | 32 | 114 | 82 | 40 | 74 | 60 | 23 |
Vaccines (3) | |||||||||
Gardasil / Gardasil 9 | 1,993 | 1,187 | 68 | 839 | 579 | 45 | 1,154 | 608 | 90 |
ProQuad / M-M-R II / Varivax | 661 | 576 | 15 | 537 | 437 | 23 | 125 | 139 | -10 |
Pneumovax 23 | 277 | 375 | -26 | 181 | 276 | -34 | 97 | 99 | -3 |
RotaTeq | 227 | 210 | 8 | 135 | 114 | 19 | 92 | 96 | -4 |
Vaqta | 48 | 51 | -6 | 32 | 32 | 2 | 16 | 19 | -19 |
Hospital Acute Care | |||||||||
Bridion | 369 | 320 | 16 | 181 | 162 | 11 | 188 | 157 | 20 |
Prevymis | 96 | 77 | 23 | 39 | 32 | 22 | 57 | 46 | 24 |
Noxafil | 64 | 79 | -19 | 19 | 13 | 44 | 45 | 66 | -31 |
Primaxin | 70 | 74 | -6 | 1 | -64 | 69 | 73 | -5 | |
Cancidas | 56 | 50 | 13 | 1 | 1 | -19 | 56 | 49 | 14 |
Invanz | 53 | 51 | 5 | (2) | 1 | * | 55 | 50 | 12 |
Zerbaxa | (2) | 43 | -105 | (1) | 20 | -106 | (1) | 23 | -104 |
Immunology | |||||||||
Simponi | 203 | 209 | -3 | 203 | 209 | -3 | |||
Remicade | 73 | 82 | -11 | 73 | 82 | -11 | |||
Neuroscience | |||||||||
Belsomra | 81 | 81 | 23 | 18 | 32 | 58 | 63 | -8 | |
Virology | |||||||||
Isentress / Isentress HD | 189 | 205 | -8 | 77 | 92 | -16 | 112 | 113 | -1 |
Cardiovascular | |||||||||
Alliance Revenue - Adempas/Verquvo (4) | 100 | 83 | 20 | 73 | 78 | -7 | 27 | 5 | * |
Adempas (5) | 59 | 55 | 7 | 0 | - 0 | 59 | 55 | 7 | |
Diabetes (6) | |||||||||
Januvia | 852 | 821 | 4 | 365 | 342 | 7 | 487 | 479 | 2 |
Janumet | 487 | 506 | -4 | 86 | 105 | -18 | 401 | 400 | |
Other Pharmaceutical (7) | 572 | 526 | 9 | 262 | 193 | 36 | 308 | 333 | -8 |
ANIMAL HEALTH | 1,417 | 1,220 | 16 | 467 | 399 | 17 | 951 | 821 | 16 |
Livestock | 864 | 758 | 14 | 190 | 165 | 15 | 675 | 593 | 14 |
Companion Animals | 553 | 462 | 20 | 277 | 234 | 18 | 276 | 228 | 21 |
Other Revenues (8) | 241 | (5) | * | 139 | 9 | * | 101 | (14) | * |
* 200% or greater | |||||||||
Sum of U.S. plus international may not equal global due to rounding. | |||||||||
(1) Only select products are shown. | |||||||||
(2) Alliance Revenue represents Merck's share of profits, which are product sales net of cost of sales and commercialization costs. | |||||||||
(3) Total Vaccines sales were $3,315 million in the third quarter of 2021 and $2,521 million in the third quarter of 2020. | |||||||||
(4) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. | |||||||||
(5) Net product sales in Merck's marketing territories. | |||||||||
(6) Total Diabetes sales were $1,417 million in the third quarter of 2021 and $1,405 million in the third quarter of 2020. | |||||||||
(7) Includes Pharmaceutical products not individually shown above. | |||||||||
(8) Other Revenues are comprised primarily of third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities. Other Revenues in the third quarter of 2021 include $135 million related to the receipt of a milestone payment for an out-licensed product. |
MERCK & CO., INC. | |||||||||
FRANCHISE / KEY PRODUCT SALES - CONTINUING OPERATIONS | |||||||||
SEPTEMBER YEAR-TO-DATE 2021 | |||||||||
(AMOUNTS IN MILLIONS) | |||||||||
(UNAUDITED) | |||||||||
Table 3b | |||||||||
Global | U.S. | International | |||||||
September YTD 2021 | September YTD 2020 | % Change | September YTD 2021 | September YTD 2020 | % Change | September YTD 2021 | September YTD 2020 | % Change | |
TOTAL SALES (1) | $35,183 | $30,570 | 15 | $16,166 | $14,301 | 13 | $19,017 | $16,269 | 17 |
PHARMACEUTICAL | 30,714 | 26,797 | 15 | 14,611 | 13,108 | 11 | 16,103 | 13,690 | 18 |
Oncology | |||||||||
Keytruda | 12,609 | 10,387 | 21 | 7,108 | 6,106 | 16 | 5,501 | 4,281 | 29 |
Alliance Revenue - Lynparza (2) | 721 | 519 | 39 | 371 | 297 | 25 | 350 | 223 | 57 |
Alliance Revenue - Lenvima (2) | 498 | 421 | 18 | 287 | 270 | 6 | 211 | 152 | 39 |
Vaccines (3) | |||||||||
Gardasil / Gardasil 9 | 4,144 | 2,941 | 41 | 1,605 | 1,209 | 33 | 2,539 | 1,732 | 47 |
ProQuad / M-M-R II / Varivax | 1,626 | 1,390 | 17 | 1,255 | 1,033 | 21 | 371 | 356 | 4 |
Pneumovax 23 | 600 | 748 | -20 | 354 | 478 | -26 | 247 | 270 | -9 |
RotaTeq | 593 | 601 | -1 | 364 | 355 | 3 | 229 | 246 | -7 |
Vaqta | 138 | 139 | -1 | 80 | 79 | 1 | 58 | 60 | -4 |
Hospital Acute Care | |||||||||
Bridion | 1,096 | 843 | 30 | 545 | 412 | 32 | 551 | 431 | 28 |
Prevymis | 270 | 200 | 35 | 111 | 87 | 28 | 159 | 113 | 40 |
Noxafil | 197 | 247 | -20 | 48 | 27 | 79 | 149 | 220 | -32 |
Primaxin | 194 | 189 | 3 | 2 | -79 | 194 | 187 | 4 | |
Cancidas | 168 | 148 | 13 | 4 | 2 | 129 | 164 | 147 | 12 |
Invanz | 157 | 159 | -1 | (2) | 7 | -128 | 159 | 152 | 5 |
Zerbaxa | (11) | 112 | -110 | (5) | 57 | -109 | (6) | 54 | -111 |
Immunology | |||||||||
Simponi | 619 | 615 | 1 | 619 | 615 | 1 | |||
Remicade | 233 | 242 | -4 | 233 | 242 | -4 | |||
Neuroscience | |||||||||
Belsomra | 238 | 244 | -2 | 56 | 67 | -17 | 183 | 177 | 3 |
Virology | |||||||||
Isentress / Isentress HD | 590 | 646 | -9 | 222 | 243 | -9 | 368 | 403 | -9 |
Cardiovascular | |||||||||
Alliance Revenue - Adempas/Verquvo (4) | 248 | 216 | 15 | 222 | 200 | 11 | 26 | 16 | 67 |
Adempas (5) | 188 | 167 | 13 | 0 | - 0 | 188 | 167 | 13 | |
Diabetes (6) | |||||||||
Januvia | 2,445 | 2,449 | 997 | 1,110 | -10 | 1,448 | 1,339 | 8 | |
Janumet | 1,449 | 1,499 | -3 | 244 | 361 | -32 | 1,205 | 1,138 | 6 |
Other Pharmaceutical (7) | 1,704 | 1,675 | 2 | 745 | 706 | 6 | 957 | 969 | -1 |
ANIMAL HEALTH | 4,307 | 3,535 | 22 | 1,363 | 1,124 | 21 | 2,944 | 2,411 | 22 |
Livestock | 2,503 | 2,145 | 17 | 508 | 448 | 13 | 1,996 | 1,697 | 18 |
Companion Animals | 1,804 | 1,390 | 30 | 855 | 676 | 26 | 948 | 714 | 33 |
Other Revenues (8) | 162 | 238 | -32 | 192 | 69 | 181 | (30) | 168 | -118 |
Sum of U.S. plus international may not equal global due to rounding. | |||||||||
(1) Only select products are shown. | |||||||||
(2) Alliance Revenue represents Merck's share of profits, which are product sales net of cost of sales and commercialization costs. | |||||||||
(3) Total Vaccines sales were $7,417 million and $6,094 million on a global basis for September YTD 2021 and 2020, respectively. | |||||||||
(4) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. | |||||||||
(5) Net product sales in Merck's marketing territories. | |||||||||
(6) Total Diabetes sales were $4,110 million and $4,177 million on a global basis for September YTD 2021 and 2020, respectively. | |||||||||
(7) Includes Pharmaceutical products not individually shown above. | |||||||||
(8) Other Revenues are comprised primarily of third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities. Other Revenues in the September year-to-date period of 2021 include $135 million related to the receipt of a milestone payment for an out-licensed product. |
MERCK & CO., INC. | ||||||||||||
PHARMACEUTICAL GEOGRAPHIC SALES - CONTINUING OPERATIONS | ||||||||||||
(AMOUNTS IN MILLIONS) | ||||||||||||
(UNAUDITED) | ||||||||||||
Table 3c | ||||||||||||
2021.0 | 2020.0 | % Change | ||||||||||
1Q | 2Q | 3Q | Sep YTD | 1Q | 2Q | 3Q | Sep YTD | 4Q | Full Year | 3Q | Sep YTD | |
TOTAL PHARMACEUTICAL | $9,238 | $9,980 | $11,496 | $30,714 | $8,905 | $8,178 | $9,714 | $26,797 | $9,813 | $36,610 | 18 | 15 |
United States | 4,294 | 4,647 | 5,670 | 14,611 | 4,308 | 3,958 | 4,842 | 13,108 | 4,903 | 18,010 | 17 | 11 |
% Pharmaceutical Sales | 46.5% | 46.6% | 49.3% | 47.6% | 48.4% | 48.4% | 49.8% | 48.9% | 50.0% | 49.2% | ||
Europe (1) | 2,276 | 2,404 | 2,445 | 7,124 | 2,116 | 1,855 | 2,171 | 6,141 | 2,314 | 8,455 | 13 | 16 |
% Pharmaceutical Sales | 24.6% | 24.1% | 21.3% | 23.2% | 23.8% | 22.7% | 22.3% | 22.9% | 23.6% | 23.1% | ||
China | 688 | 944 | 1,278 | 2,910 | 628 | 600 | 764 | 1,992 | 670 | 2,661 | 67 | 46 |
% Pharmaceutical Sales | 7.4% | 9.5% | 11.1% | 9.5% | 7.1% | 7.3% | 7.9% | 7.4% | 6.8% | 7.3% | ||
Japan | 607 | 637 | 614 | 1,858 | 561 | 601 | 648 | 1,810 | 704 | 2,514 | -5 | 3 |
% Pharmaceutical Sales | 6.6% | 6.4% | 5.3% | 6.0% | 6.3% | 7.3% | 6.7% | 6.8% | 7.2% | 6.9% | ||
Asia Pacific (other than China and Japan) | 437 | 442 | 450 | 1,329 | 411 | 377 | 411 | 1,200 | 414 | 1,614 | 9 | 11 |
% Pharmaceutical Sales | 4.7% | 4.4% | 3.9% | 4.3% | 4.6% | 4.6% | 4.2% | 4.5% | 4.2% | 4.4% | ||
Latin America | 353 | 379 | 434 | 1,166 | 314 | 312 | 372 | 998 | 371 | 1,369 | 17 | 17 |
% Pharmaceutical Sales | 3.8% | 3.8% | 3.8% | 3.8% | 3.5% | 3.8% | 3.8% | 3.7% | 3.8% | 3.7% | ||
Eastern Europe/Middle East/Africa | 357 | 318 | 362 | 1,037 | 353 | 309 | 289 | 948 | 251 | 1,199 | 25 | 9 |
% Pharmaceutical Sales | 3.9% | 3.2% | 3.1% | 3.4% | 4.0% | 3.8% | 3.0% | 3.5% | 2.6% | 3.3% | ||
Canada | 160 | 157 | 164 | 482 | 159 | 121 | 169 | 449 | 149 | 599 | -3 | 7 |
% Pharmaceutical Sales | 1.7% | 1.6% | 1.4% | 1.6% | 1.8% | 1.5% | 1.7% | 1.7% | 1.5% | 1.6% | ||
Other | 66 | 52 | 79 | 197 | 55 | 45 | 48 | 151 | 37 | 189 | 65 | 30 |
% Pharmaceutical Sales | 0.8% | 0.4% | 0.8% | 0.6% | 0.5% | 0.6% | 0.6% | 0.6% | 0.3% | 0.5% | ||
Sum of quarterly amounts may not equal year-to-date amounts due to rounding. | ||||||||||||
(1) Europe represents all European Union countries, the European Union accession markets and the United Kingdom. |
&"Arial,Bold"&28
MERCK & CO., INC. | ||||
OTHER (INCOME) EXPENSE, NET - GAAP | ||||
(AMOUNTS IN MILLIONS) | ||||
(UNAUDITED) | ||||
Table 4 | ||||
OTHER (INCOME) EXPENSE, NET | ||||
3Q21 | 3Q20 | Sep YTD 2021 | Sep YTD 2020 | |
Interest income | $ (7) | $ (9) | $ (27) | $ (48) |
Interest expense | 196 | 203 | 597 | 624 |
Exchange losses | 46 | 10 | 202 | 89 |
Income from investments in equity securities, net (1) | (683) | (360) | (1,535) | (964) |
Net periodic defined benefit plan cost (credit) other than service cost | 40 | (88) | (159) | (259) |
Other, net | (42) | (68) | (85) | (79) |
Total | $ (450) | $ (312) | $ (1,007) | $ (637) |
(1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while ownership interests in investment funds are accounted for on a one quarter lag. |
Attachments
- Original document
- Permalink
Disclaimer
Merck & Co. Inc. published this content on 28 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 October 2021 11:02:25 UTC.